To differentiate between these possibilities, NDD mice were treated with Valproic acid (VPA, 200mg/kg/day), an HDAC2 inhibitor [41] approved by the FDA for use in humans [42]. This evidence concerns the gene HDAC2 and Neurodevelopmental delay.